Cooperative Agreement UG1CA308623
Award Date 4/20/26
Completion Date 2/29/32
Dollars Obligated $369K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Pennsylvania, USA
Similar Awards
- Federal Cooperative Agreement Summary The University of Pennsylvania received a $2.24M cooperative agreement from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with completion scheduled for August 31, 2028. The award supports the development and clinical testing of TCR1020, a next-generation T cell receptor (TCR) therapy targeting mutant KRAS G12V mutations in solid tumors. The project delivers three primary research and...
- Federal Cooperative Agreement Summary The University of Pennsylvania received a $1.59 million Cooperative Agreement from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) awarded September 15, 2025, with an ultimate completion date of August 31, 2027. The I-LEARN (Increasing Lung Cancer Screening Effectiveness and Access Through Regional Networks) study compares the effectiveness of selection approaches and implementation strategy...
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $366,921.00 to the Trustees of Indiana University (Indiana University Simon Comprehensive Cancer Center) under the Cancer Treatment Research program (CFDA 93.395), with an award date of April 20, 2026 and ultimate completion date of February 29, 2032. Under this agreement, Indiana University will serve as a lead academic participating site within the National Clinical Trial...
- Cooperative Agreement Summary The National Cancer Institute awarded a $556,865 Cooperative Agreement to Trustees of Tufts College under the Cancer Biology Research program (CFDA 93.396) on September 1, 2025, with a completion date of August 31, 2030. This five-year research initiative investigates stiffness-mediated genetic selection of cells, examining how mechanical properties of substrates select for cellular variants adapted to growth on soft or stiff environments. The research extends...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Cooperative Agreement Summary The University of Pittsburgh received a $360,643 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through August 31, 2030. This award supports preanalytical validation research for circulating tumor DNA (ctDNA) and tumor-derived exosomes (TEX) as biomarkers of postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC)....
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $962,104 to the Research Institute at Nationwide Children's Hospital, effective July 3, 2025 through June 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and clinical testing of novel therapeutic approaches targeting mutant-MYOD1 driven rhabdomyosarcoma (RMS), the most common soft tissue cancer in the pediatric population. The...
- Grant Award Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $975,000 to Rutgers The State University of New Jersey on March 21, 2026, under the Cancer Treatment Research program (CFDA 93.395) with a completion date of February 29, 2032. This award supports clinical trial infrastructure and administrative services for the Rutgers Cancer Institute and RWJBarnabas Health System. The initiative facilitates expanded cancer clinical research across multiple...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $639,882 to the University of North Carolina at Chapel Hill (UNC-CH), Office of Sponsored Research, effective August 1, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Pennsylvania a Project Grant totaling $178,893 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. Dr. Naomi Haas, a genitourinary medical oncologist at the Abramson Cancer Center, will lead initiatives focused on developing and translating immunotherapy clinical trials in renal cell cancer (RCC) for delivery through the National Cancer Clinical Trials...